Decoy Therapeutics
DCOY
10 hedge funds and large institutions have $630K invested in Decoy Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 5 → 10 (+5)
0% more ownership
Funds ownership: 0% → 0% (+0%)
1% less capital invested
Capital invested by funds: $637K → $630K (-$7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$119K |
| 2 |
Millennium Management
New York
|
+$39.6K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$39.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$39.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWB
RMR Wealth Builders
Montclair,
New Jersey
|
-$4K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
DCOY Hedge Fund Activity: Q3 2020 in Review
10 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2020, worth a combined $630K — down 1.1% from $637K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DCOY positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $119K. The largest seller was RMR Wealth Builders, cutting an estimated $4K.
- 10 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $630K of Decoy Therapeutics stock for Q3 2020, down 1.1% quarter-over-quarter.
- 5 funds opened new Decoy Therapeutics positions in Q3 2020 and 0 closed out, a net change of +5 holders.
- The largest Decoy Therapeutics buyer in Q3 2020 was Kepos Capital, an estimated $119K added.
- The largest Decoy Therapeutics seller in Q3 2020 was RMR Wealth Builders, an estimated $4K sold.
Based on aggregated 13F filings for Q3 2020.